Abstract
This review aims to summarize present approaches employed in delivering drugs to the central nervous system. Changes in blood-brain barrier (BBB) function have been reported in several neurological disorders. A brief description of the blood brain barrier and the main pathologies related to this barrier disfunction are described. Treatments for these disorders are based on several available strategies for delivering drugs into the brain, through circumvention of the BBB, as disruption of the BBB, prodrugs, molecular Trojan horses, among others. Particular attention will be placed on nanocarriers and more specifically on polymeric nanoparticles, which are presented as the most promising strategy for CNS delivery, helping drugs to be targeted more efficiently to the brain. This also allows attacking previously untreatable disorders such as brain tumors and other neurodegenerative diseases. New strategies and technologies commercialized by different pharmaceutical companies are also included.
Keywords: Blood-brain barrier, brain targeting, CNS delivery, drug delivery, nanocarriers, nanostructures, polymeric nanoparticles, neurodegerative diseases, brain tumors, BBB disfunction
Current Medicinal Chemistry
Title: Nanostructures for Drug Delivery to the Brain
Volume: 18 Issue: 34
Author(s): L. Martin-Banderas, M. A. Holgado, J. L. Venero, J. Alvarez-Fuentes and M. Fernandez-Arevalo
Affiliation:
Keywords: Blood-brain barrier, brain targeting, CNS delivery, drug delivery, nanocarriers, nanostructures, polymeric nanoparticles, neurodegerative diseases, brain tumors, BBB disfunction
Abstract: This review aims to summarize present approaches employed in delivering drugs to the central nervous system. Changes in blood-brain barrier (BBB) function have been reported in several neurological disorders. A brief description of the blood brain barrier and the main pathologies related to this barrier disfunction are described. Treatments for these disorders are based on several available strategies for delivering drugs into the brain, through circumvention of the BBB, as disruption of the BBB, prodrugs, molecular Trojan horses, among others. Particular attention will be placed on nanocarriers and more specifically on polymeric nanoparticles, which are presented as the most promising strategy for CNS delivery, helping drugs to be targeted more efficiently to the brain. This also allows attacking previously untreatable disorders such as brain tumors and other neurodegenerative diseases. New strategies and technologies commercialized by different pharmaceutical companies are also included.
Export Options
About this article
Cite this article as:
Martin-Banderas L., A. Holgado M., L. Venero J., Alvarez-Fuentes J. and Fernandez-Arevalo M., Nanostructures for Drug Delivery to the Brain, Current Medicinal Chemistry 2011; 18 (34) . https://dx.doi.org/10.2174/092986711798184262
DOI https://dx.doi.org/10.2174/092986711798184262 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Theory and Application of Microdialysis in Pharmacokinetic Studies
Current Drug Metabolism Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Current Medicinal Chemistry Regulatory Mechanism of the Gastric Hyperemic Response Following Barrier Disruption: Roles of Cyclooxygenase-1, the Prostaglandin E<sub>2</sub>/EP1 Receptor and Sensory Neurons
Current Pharmaceutical Design Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Role of Calcitonin Gene-Related Peptide in Gastric Mucosal Defence and Healing
Current Pharmaceutical Design Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Synthesis and Biological Activity of 3-(2, 8, 9-trioxa-aza-1-germatricyclo [3. 3. 3. 0] undecane-1-yl)-caffeic Acid
Medicinal Chemistry Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Involvement of Orexigenic Peptides in the Mechanism of Gastric Mucosal Integrity and Healing of Chronic Gastric Ulcers
Current Pharmaceutical Design